Overall Survival in Patients With Platinum-Sensitive Recurrent Serous Ovarian Cancer Receiving Olaparib Maintenance Monotherapy

PracticeUpdate
  

TAKE-HOME MESSAGE

• This study included 265 patients with BRCA-mutated platinum-sensitive recurrent serous ovarian cancer who were randomized to receive olaparib or placebo. A survival advantage was observed in all patients who received olaparib compared with placebo. A total of 22% of patients receiving olaparib and 9% of patients receiving placebo reported serious adverse events.
  
• These data support the tolerability and long-term benefit of maintenance olaparib in this patient population.

Additional Info

• Article Citation

The Lancet Oncology

Overall Survival in Patients With Platinum-Sensitive Recurrent Serous Ovarian Cancer Receiving Olaparib Maintenance Monotherapy: An Updated Analysis From a Randomised, Placebo-Controlled, Double-Blind, Phase 2 Trial

Lancet Oncol 2016 Sep 08;[EPub Ahead of Print], JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, C Scott, W Meier, R Shapira-Frommer, T Safra, D Matei, A Fielding, S Spencer, P Rowe, E Lowe, D Hodgson, MA Sovak, U Matulonis